Biofourmis

Biofourmis is a global leader in AI-powered remote patient monitoring (RPM) and digital therapeutics (DTx), utilizing its proprietary Biovitals® platform to deliver personalized, predictive care. By 2026, the company has solidified its technical architecture around a high-frequency data ingestion engine that processes multimodal physiological signals from medical-grade wearables like the Everion® sensor. Its core value proposition lies in its FDA-cleared algorithms that establish a baseline for each patient, detecting subtle physiological changes to predict clinical deterioration up to days before an event occurs. This 'hospital-at-home' model is integrated directly into health system workflows, reducing readmission rates and optimizing resource allocation. For pharmaceutical partners, Biofourmis provides a decentralized clinical trial (DCT) platform that uses digital biomarkers to objectively measure treatment efficacy in real-world settings. The technical stack emphasizes deep interoperability with major EHR systems via HL7 FHIR and a robust API layer for custom application development. Its 2026 market position is defined by its shift toward specialized care pathways in oncology, cardiology, and respiratory health, leveraging AI to automate medication titration and intervention alerts at scale.